The haemolytic uraemic syndromes (HUS) are a heterogeneous group of disorders characterized by haemolytic anaemia, thrombocytopaenia and renal failure occurring predominantly in infants and young children. The disorder, which is acknowledged as the commonest cause of acute renal failure in children in Britain, is increasingly recognized in adults. 23 Two broad subtypes are now recognized: the first is common in children and is associated with a diarrhoeal prodrome (D +), whereas the second is rare in childhood and not associated with antecedent diarrhoea (D - 2829 The risk of such involvement is reduced by control of hypertension and the correction of electrolyte imbalance; however, severe cerebral dysfunction may still occur. Anticonvulsants should be given if required and elective ventilation instituted should the patient be comatose or the level of consciousness become impaired. Computed tomography and cerebral perfusion scanning with intracranial pressure monitoring may be important adjuncts to effective treatment as either cerebral oedema and elevated intracranial pressure or vascular involvement with normal intracranial pressure may be present. Hyperventilation, mannitol, to be given cautiously ifthe child is anuric, and fluid restriction should be instituted in the presence of raised intracranial pressure whereas such measures may impair cerebral perfusion should a cerebral vasculopathy be present. Plasma exchange and/or prostacyclin infusion have been used in the management of patients with presumed central nervous system vascular disease. 30 The outcome of the majority of cases of D + HUS is good with supportive treatment and appropriate renal failure management. A few children with D + HUS die in the acute phase of the illness with complications ofacute renal failure, fulminant colitis or central nervous system involvement. Thus the indications for plasma therapy remain controversial. Until evidence from controlled trials supporting the use of plasma exchange and prostacyclin infusion becomes available, such treatments should be restricted to the minority of patients with severe complications associated with a poor prognosis such as those with cerebral or severe gastrointestinal involvement and a high polymorphonuclear count at presentation. 37 Patients with D -HUS have a poor prognosis; there is a significant mortality and morbidity with the majority developing some degree of renal impairment and hypertension.38'39 Renal failure is controlled with early dialysis and hypertension with volume depletion if necessary, and captopril or a prostacyclin infusion if required. On the basis of the observed deficiency of prostacyclin in some cases and experience in the management of thrombotic thrombocytopaenic purpura many centres treat D -HUS with fresh plasma.' Some cases appear to respond to plasma exchange but not fresh plasma alone. We treat children with D -HUS with plasma exchange using an infusion of fresh frozen plasma at the end of the procedure. Relapsing D -HUS is managed by a programme of intermittent plasma exchange at increasing intervals for a few months after the last relapse. The cases are too few, however, for a controlled clinical trial to be instigated, but empirically we have found that acute renal failure may be reversed but that there remains a probability of relapse several months after the last plasma exchange.
Treatment of patients with neuraminidaseassociated HUS may be problematic. Most adult plasma contains antibodies against the ThomsenFreidenreich antibody and plasma infusion or whole blood transfusion in such patients may be deleterious, accentuating the polyagglutination and haemolysis. These patients should receive washed red cells and albumin solutions thus avoiding additional agglutinating antibody, and exchange transfusion should be considered.
